Savant Capital LLC Has $1.25 Million Stock Holdings in STERIS plc $STE

Savant Capital LLC raised its stake in STERIS plc (NYSE:STE) by 69.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,183 shares of the medical equipment provider’s stock after purchasing an additional 2,131 shares during the period. Savant Capital LLC’s holdings in STERIS were worth $1,245,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Ballentine Partners LLC acquired a new stake in STERIS during the first quarter worth approximately $267,000. CWM LLC lifted its holdings in STERIS by 42.1% during the 1st quarter. CWM LLC now owns 3,518 shares of the medical equipment provider’s stock worth $797,000 after purchasing an additional 1,042 shares during the last quarter. Edgestream Partners L.P. boosted its stake in STERIS by 36.0% in the 1st quarter. Edgestream Partners L.P. now owns 16,055 shares of the medical equipment provider’s stock valued at $3,639,000 after purchasing an additional 4,251 shares during the period. Apollon Wealth Management LLC grew its holdings in STERIS by 3.9% in the 1st quarter. Apollon Wealth Management LLC now owns 2,588 shares of the medical equipment provider’s stock valued at $587,000 after buying an additional 96 shares in the last quarter. Finally, Wealthfront Advisers LLC increased its position in STERIS by 53.4% during the 1st quarter. Wealthfront Advisers LLC now owns 2,883 shares of the medical equipment provider’s stock worth $653,000 after buying an additional 1,004 shares during the period. Institutional investors own 94.69% of the company’s stock.

STERIS Price Performance

STERIS stock opened at $267.82 on Thursday. The stock has a market capitalization of $26.38 billion, a price-to-earnings ratio of 41.01 and a beta of 1.02. STERIS plc has a 52-week low of $200.98 and a 52-week high of $268.30. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.53 and a current ratio of 2.22. The stock’s 50 day moving average price is $245.36 and its two-hundred day moving average price is $239.86.

STERIS (NYSE:STE) last released its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.38 by $0.09. The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. STERIS had a net margin of 11.61% and a return on equity of 14.17%. During the same quarter in the previous year, the company earned $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. On average, equities analysts predict that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Tuesday, November 18th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, November 18th. STERIS’s payout ratio is presently 36.21%.

Insider Transactions at STERIS

In other news, VP Renato Tamaro sold 3,204 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $249.24, for a total transaction of $798,564.96. Following the completion of the sale, the vice president owned 7,221 shares in the company, valued at $1,799,762.04. The trade was a 30.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Daniel A. Carestio sold 159 shares of the stock in a transaction on Monday, October 6th. The stock was sold at an average price of $241.82, for a total value of $38,449.38. Following the completion of the transaction, the chief executive officer owned 51,096 shares in the company, valued at approximately $12,356,034.72. This represents a 0.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 1.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on STE shares. KeyCorp lifted their target price on STERIS from $277.00 to $288.00 and gave the company an “overweight” rating in a research report on Tuesday, July 22nd. Morgan Stanley increased their target price on shares of STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, August 8th. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 14th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $273.50.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.